High rates of freedom from disease, overall survival for standard-dose, with lower-dose EPOCH-R treatment.
Drug designed to inhibit enzyme that cancer cells need to spread is granted "breakthrough therapy" status by FDA.
Oncologists are adding new agents to their arsenal against mantle cell lymphoma.
Vaccines and monoclonal antibodies are promising new treatments for patients with follicular lymphoma.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|